<SEC-DOCUMENT>0001171843-16-008208.txt : 20160226
<SEC-HEADER>0001171843-16-008208.hdr.sgml : 20160226
<ACCEPTANCE-DATETIME>20160226165255
ACCESSION NUMBER:		0001171843-16-008208
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20160226
DATE AS OF CHANGE:		20160226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-202466
		FILM NUMBER:		161462850

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>posam_022616.htm
<DESCRIPTION>POS AM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>As filed with the Securities and Exchange Commission on January 26,
2016</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Registration No. 333-202466 </B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 12pt 0 0"><B>POST-EFFECTIVE AMENDMENT NO. 1 TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 6pt 0 0"><B>FORM S-3</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 6pt 0 0"><B>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 6pt 0 0"><B>BioCryst Pharmaceuticals, Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Exact name of registrant as specified in its charter)</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <td style="width: 50%; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>62-1413174</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt"><font style="font-size: 10pt"><i>(State or other jurisdiction of incorporation or organization)</i></font></td>
    <td style="text-align: center; font-size: 10pt"><font style="font-size: 10pt"><i>(I.R.S. Employer Identification Number)</i></font></td></tr>
</table>
<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>4505 Emperor Blvd., Suite 200</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Durham, North Carolina 27703</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(919) 859-1302</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Address, including zip code, and telephone number, including area
code, of registrant&rsquo;s principal executive offices)</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Jon P. Stonehouse</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>President and Chief Executive Officer</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>4505 Emperor Blvd., Suite 200</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Durham, North Carolina 27703</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(919) 859-1302</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Name, address, including zip code, and telephone number, including
area code, of agent for service)</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><I>With a copy to:</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Brian Lane, Esq.<BR>
Robyn Zolman, Esq.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Gibson, Dunn &amp; Crutcher LLP</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>1050 Connecticut Avenue, NW</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><FONT STYLE="font-size: 10pt"><B>Washington</B></FONT><B>, DC 20036</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(202) 955-8500</B></P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><B>Approximate date of commencement of proposed sale to the public:</B> From time to
time after the effective date of this Registration Statement, as determined by market conditions.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><FONT STYLE="font-size: 10pt">If the only securities being registered on this Form
are being offered pursuant to dividend or interest reinvestment plans, check the following box: </FONT>[_]<FONT STYLE="font-size: 10pt">
</FONT></P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><FONT STYLE="font-size: 10pt">If any of the securities being registered on this Form
are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, please check the following box: </FONT>[X]</P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><FONT STYLE="font-size: 10pt">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. </FONT>[_]</P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><FONT STYLE="font-size: 10pt">If this Form is a post-effective amendment filed pursuant
to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. </FONT>[_]</P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><FONT STYLE="font-size: 10pt">If this Form is a registration statement pursuant to
General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. </FONT>[_]</P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"><FONT STYLE="font-size: 10pt">If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. </FONT>[_]</P>

<P STYLE="font-size: 10pt; margin: 6pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 6pt 0 0">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated
filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 56%"><font style="font-size: 10pt">Large accelerated filer </font>[X]</td>
    <td style="width: 44%"><font style="font-size: 10pt">Accelerated filer </font>[_]</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Non-accelerated filer </font>[_]<font style="font-size: 10pt">&nbsp;(do not check if a smaller reporting company)</font></td>
    <td><font style="font-size: 10pt">Smaller reporting company </font>[_]</td></tr>
</table>
<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.25in; margin: 6pt 0 0 0.25in">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>CALCULATION OF REGISTRATION FEE</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 36%; text-decoration: underline"><font style="font-size: 10pt"><b><u>Title of Each Class of Securities to be Registered</u></b></font></td>
    <td style="vertical-align: bottom; width: 17%; text-align: center"><font style="font-size: 10pt"><b>Amount to be <u>Registered(1)</u></b></font></td>
    <td style="vertical-align: top; width: 15%; text-align: center"><font style="font-size: 10pt"><b>Proposed Maximum Offering Price </b></font><br>
<font style="font-size: 10pt"><b><u>Per Unit(3)</u></b></font></td>
    <td style="vertical-align: bottom; width: 17%; text-align: center"><font style="font-size: 10pt"><b>Proposed Maximum Aggregate</b></font><br>
<font style="font-size: 10pt"><b><u>Offering Price</u></b></font></td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><font style="font-size: 10pt"><b>Amount of <u>Registration Fee(4)</u></b></font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; margin: 0">Common Stock, $0.01 par value(2)</P>
        <P STYLE="font-size: 10pt; margin: 0">Preferred Stock, $0.01 par value(2)</P>
        <P STYLE="font-size: 10pt; margin: 0">Depositary Shares(2)</P>
        <P STYLE="font-size: 10pt; margin: 0">Stock Purchase Contracts(2)</P>
        <P STYLE="font-size: 10pt; margin: 0">Warrants(2)</P>
        <P STYLE="font-size: 10pt; margin: 0">Units(2)</P>
        <P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0"><b><u>Total</u></b></P></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">$150,000,000</font></td>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">N/A</P></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">$150,000,000</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">$15,105</font></td></tr>
</table>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>There are being registered under this registration statement such indeterminate number of securities of each identified class
of the registrant, all at indeterminate prices, as shall have an aggregate initial offering price not to exceed $150,000,000 or
the equivalent amount denominated in one or more foreign currencies. Any securities registered under this registration statement
may be sold separately or as units with other securities registered hereunder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Pursuant to Rule 457(i) under the Securities Act, the securities registered hereunder also include such indeterminate number
of shares of common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units as may be issued upon
exercise, settlement, exchange or conversion of any securities registered hereunder that provide for those issuances. In addition,
pursuant to Rule 416 under the Securities Act, the securities registered hereunder include such indeterminate number of securities
as may be issuable with respect to the securities being registered hereunder as a result of stock splits, stock dividends or similar
transactions.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>The proposed maximum offering price per unit is not specified as to each class of securities to be registered, pursuant to
General Instruction II.D of Form S-3 under the Securities Act. The proposed maximum offering price per unit will be determined
from time to time by the registrant in connection with, and at the time of, the issuance of the securities registered hereunder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Calculated pursuant to Rule 457(o) under the Securities Act.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 12pt 0 0"><B>The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the Securities
Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said
Section&nbsp;8(a)&nbsp;may determine.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">This Post-Effective Amendment No. 1 to the Registration
Statement on Form S-3 (Commission File No. 333-202466) (the &ldquo;Registration Statement&rdquo;) of BioCryst Pharmaceuticals,
Inc. is being filed for the purpose of amending the Registration Statement to reflect that the registrant is no longer a well-known
seasoned issuer, as defined in Rule 405 under the Securities Act, because the worldwide market value of its outstanding common
stock held by non-affiliates was less than $700 million as of the registrant&rsquo;s most recent determination date. This Post-Effective
Amendment is being filed to convert the Registration Statement to a non-automatic shelf registration statement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white; color: #DE1A1E"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0; background-color: white; color: #DE1A1E"><B>The information in this prospectus is not complete
and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission
becomes effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities
in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white; color: #DE1A1E"><B>SUBJECT TO COMPLETION, DATED
FEBRUARY 26, 2016</B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>PROSPECTUS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>$150,000,000</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Common Stock<BR>
Preferred Stock<BR>
Depositary Shares<BR>
Stock Purchase Contracts<BR>
Warrants<BR>
Units</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0 9pt">By this prospectus, we may from time to time offer securities
to the public. We will provide specific terms of these securities in supplements to this prospectus. You should read this prospectus,
the applicable prospectus supplement, and the information incorporated by reference in this prospectus and the applicable prospectus
supplement carefully before you invest.</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0 9pt">Our common stock, par value $0.01 per share, trades on the
NASDAQ Global Select Market under the symbol &ldquo;BCRX.&rdquo;</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0 9pt">We have not authorized anyone else to make additional representations
or to provide you with information other than information provided or incorporated by reference in this prospectus or any prospectus
supplement. We take no responsibility for, and can provide no assurances as to the reliability of, any other information that others
may give you or representations that others may make. We are not making or soliciting an offer of any securities other than the
securities described in this prospectus and any prospectus supplement. We are not making or soliciting an offer of these securities
in any state or jurisdiction where the offer is not permitted or in any circumstances in which such offer or solicitation is unlawful.
You should not assume that the information contained or incorporated by reference in this prospectus or any prospectus supplement
is accurate as of any date other than the date on the front of those documents.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">______________</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0 9pt"><B>Investing in these securities involves a high degree of
risk. See &ldquo;Risk Factors&rdquo; on page 2 of this prospectus, in the applicable prospectus supplement we will deliver with
this prospectus and in the documents incorporated herein and therein by reference.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">______________</P>

<P STYLE="font-size: 10pt; text-indent: 19.2pt; margin: 12pt 0 0 8.4pt">The securities may be sold by us to or through underwriters
or dealers, directly to purchasers or through agents designated from time to time, or through a combination of these methods. For
additional information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this
prospectus. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered,
the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in a prospectus
supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set
forth in a prospectus supplement. This prospectus may not be used to sell any securities unless accompanied by a prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0 9pt"><B>Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2016.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0; text-align: right"><U>Page</U></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">ABOUT THIS PROSPECTUS</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0pt">i</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">PROSPECTUS SUMMARY</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">RISK FACTORS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">2</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">USE OF PROCEEDS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">DESCRIPTION OF COMMON STOCK, PREFERRED STOCK AND DEPOSITARY SHARES</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">DESCRIPTION OF STOCK PURCHASE CONTRACTS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">DESCRIPTION OF WARRANTS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">DESCRIPTION OF UNITS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">PLAN OF DISTRIBUTION</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">LEGAL MATTERS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">EXPERTS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">WHERE YOU CAN FIND MORE INFORMATION</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">This prospectus is part of a registration statement on Form S-3
that we filed with the Securities and Exchange Commission, or the SEC, using a &ldquo;shelf&rdquo; registration or continuous offering
process. Under this registration statement, we may sell any combination of the securities described in this prospectus from time
to time, either separately or in units, in one or more offerings. Together, these offerings may total up to $150.0 million.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">This prospectus provides you with a general description of the
securities we may offer. Each time we sell securities, we will provide a prospectus supplement containing specific information
about the terms of that offering. That prospectus supplement may add, update or change information contained in this prospectus
and will also include the following information:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the type and amount of securities that we propose to sell;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the public offering price of the securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the names of any underwriters, agents or dealers through or to which the securities will be sold;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any compensation of those underwriters, agents or dealers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>information about any securities exchanges or automated quotation systems on which the securities will be listed or traded;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any risk factors applicable to the securities that we propose to sell; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any other material information about the offering and sale of the securities.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">If there is any inconsistency between the information in this
prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement. You should read both
this prospectus and any prospectus supplement together with the additional information described under the heading &ldquo;Where
You Can Find More Information.&rdquo; The registration statement containing this prospectus, including the exhibits to the registration
statement, provides additional information about us and the securities offered under this prospectus. The registration statement,
including the exhibits, can be read at the SEC&rsquo;s website or at the SEC&rsquo;s offices referenced under the heading &ldquo;Where
You Can Find More Information.&rdquo;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">All references to &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo;
or &ldquo;us&rdquo; refer solely to BioCryst Pharmaceuticals, Inc. and not to the persons who manage us or sit on our Board of
Directors. All trade names used in this prospectus are either our registered trademarks or trademarks of their respective holders.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">This summary highlights information contained elsewhere or incorporated
by reference into this prospectus. Because it is a summary, it does not contain all of the information that you should consider
before investing in our securities. You should read this entire prospectus carefully, including the section entitled &ldquo;Risk
Factors&rdquo; and the documents that we incorporate by reference into this prospectus, before making an investment decision.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>Business of BioCryst Pharmaceuticals, Inc.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt">We are a biotechnology company that
designs, optimizes and develops novel small molecule drugs that block key enzymes involved in <FONT STYLE="background-color: white">the
pathogenesis of diseases. </FONT></FONT>We focus on the treatment of rare diseases in which significant unmet medical needs exist
and that align with our capabilities and expertise. We integrate the disciplines of biology, crystallography, medicinal chemistry
and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug
design. Structure-guided drug design is a drug discovery approach by which we design synthetic compounds from detailed structural
knowledge of the active sites of enzyme targets associated with particular diseases. We use X-ray crystallography, computer modeling
of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site
characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many vital biological
reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme and thereby prevent its catalytic
activity.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We are a Delaware corporation originally founded in 1986. Our
principal executive offices are located at 4505 Emperor Blvd. Suite 200, Durham, North Carolina 27703, and our telephone number
is (919) 859-1302. For more information about us, please visit our website at http://www.biocryst.com. The information on our web
site is not incorporated by reference into this prospectus.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>RISK FACTORS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Investing in our securities involves risks. Our business is influenced
by many factors that are difficult to predict and beyond our control and that involve uncertainties that may materially affect
our business, results of operations, financial condition or cash flows, or the value of these securities. These risks and uncertainties
are described in the risk factors section of the documents that are incorporated by reference in this prospectus. Any subsequent
prospectus supplement may contain a discussion of additional risks applicable to an investment in us and the particular type of
securities we are offering under such prospectus supplement. You should carefully consider all of the information contained in
or incorporated by reference in this prospectus and in the applicable prospectus supplement before you invest in our securities.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>INFORMATION REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">This prospectus and any subsequent prospectus supplement, including
the information we incorporate by reference, contain forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which are subject to the &ldquo;safe harbor&rdquo; created in
Section 21E. All statements other than statements of historical facts contained in this prospectus, any subsequent prospectus supplement
and the information we incorporate by reference are forward-looking statements. These forward-looking statements can generally
be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; the
negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations,
objectives, goals or prospects are also forward-looking statements. These forward-looking statements include, but are not limited
to, statements about:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the initiation, timing, progress and results of our preclinical testing, clinical trials, and to the extent applicable, post-marketing
commitments, for our HAE product candidates, RAPIVAB, BCX4430, and our other research and development efforts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the further preclinical development, clinical development, commercialization, or post-marketing studies by either us or partners
of our product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the potential funding from our contracts <FONT STYLE="background-color: white">with the Biomedical Advanced Research and Development
Authority within the United States Department of Health and Human Services (&ldquo;BARDA/HHS&rdquo;) and the National Institute
of Allergy and Infectious Diseases within the United States Department of Health and Human Services (&ldquo;NIAID/HHS&rdquo;) for
the development of BCX4430</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties
or profit from commercial sales of RAPIVAB by us or our partners;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the implementation of our business model, strategic plans for our business, products, product candidates and technology;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to establish and maintain collaborations or out-license rights to our drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>plans, programs, progress and potential success of our collaborations, including Sequirus UK Limited (&ldquo;SUL&rdquo;) for
RAPIVAB, Mundipharma International Holdings Limited (&ldquo;Mundipharma&rdquo;) for forodesine and Shionogi &amp; Co., Ltd. (&ldquo;Shionogi&rdquo;)
and Green Cross Corporation (&ldquo;Green Cross&rdquo;) for peramivir in their territories;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>JPR Royalty Sub LLC&rsquo;s (&ldquo;Royalty Sub&rdquo;) ability to service its payment obligations in respect of the PhaRMA
Notes, and our ability to benefit from our equity interest in Royalty Sub;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product
candidates and technology;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to operate our business without infringing the intellectual property rights of others;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>estimates of our expenses, revenues, capital requirements and our needs for additional financing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the timing or likelihood of regulatory filings or regulatory agreements, deferrals and approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to raise additional capital to fund our operations;</TD></TR></TABLE>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our financial performance; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>competitive companies, technologies and our industry.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus, any subsequent prospectus supplement and the documents
incorporated by reference. Any forward-looking statement reflects our current views with respect to future events and is subject
to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future
growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason,
even if new information becomes available in the future.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Discussions containing these forward-looking statements are also
contained in &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; incorporated
by reference from our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarters ended since our
most recent Annual Report, our Current Reports on Form 8-K, as well as any future amendments we make to those filings or future
filings with the SEC.</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>USE OF PROCEEDS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Except as otherwise described in the applicable prospectus supplement,
the net proceeds we expect to receive from the sale of any securities offered hereunder will be added to our general funds and
used for general corporate purposes, which may include, but are not limited to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>funding development, manufacturing and regulatory activities for avoralstat;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>funding development, manufacturing and regulatory activities for BCX7353;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>funding development, manufacturing and regulatory activities for other second generation HAE compounds;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>post-approval commitments such as the pediatric study for RAPIVAB&trade;;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>pre-launch commercial activities for the HAE market;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the advancement of development activities on other rare disease targets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>funding our research and development efforts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>capital expenditures and enhancing our laboratory facilities; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>general working capital needs.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may also use a portion of the net proceeds to acquire or invest
in businesses, assets, products and technologies that are complementary to our own, although we are not currently contemplating
or negotiating any such acquisitions or investments.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The amount and timing of these expenditures will depend on a
number of factors, including the progress of our research and development efforts and amounts received under our existing and
any future government contracts and collaboration arrangements, as well as the amount of cash used in our operations. Accordingly,
our management will have broad discretion in the application of these proceeds, and investors will be relying on the judgment
of our management with regard to the use of these proceeds. Pending application of the net proceeds as described above, we intend
to invest the net proceeds in investment grade interest bearing instruments.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>DESCRIPTION OF COMMON STOCK, PREFERRED
STOCK AND DEPOSITARY SHARES</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The following summary description of our capital stock summarizes
general terms and provisions that apply to the capital stock. Because this is only a summary, it does not contain all of the information
that may be important to you. This summary is subject to and qualified in its entirety by reference to our restated certificate
of incorporation, as amended, by-laws, as amended, and the rights agreement, as amended, each of which are on file with the SEC.
See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>Authorized and Outstanding Capital Stock</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Our authorized capital stock consists of 200,000,000 shares of
common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par value $0.01 per share, of which 200,000 shares
are designated Series B Junior Participating Preferred Stock with a par value of $0.001 per share. On February 24, 2016, there
were 73,629,816 shares of common stock outstanding and no shares of preferred stock outstanding.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>Common Stock</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Holders of our common stock are entitled to one vote per share
on all matters submitted to a vote of stockholders and may not cumulate votes for the election of directors. Common stockholders
have the right to receive dividends as and when declared by the Board of Directors from funds legally available therefor, subject
to any preferential dividend rights of any preferred stock then outstanding. Upon our dissolution or liquidation, common stockholders
are entitled to receive all assets legally available for distribution to stockholders, subject to any preferential rights of any
preferred stock then outstanding. Holders of common stock have no preemptive rights and have no rights to convert their common
stock into any other securities.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>Preferred Stock</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Preferred stock may be issued from time to time in one or more
series, each such series to have such terms as determined by our Board of Directors. Our Board of Directors has the authority to
determine and fix such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating,
optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation dividend
rights, conversion rights, redemption privileges and liquidation preferences, without further vote or action by our stockholders.
We will distribute a prospectus supplement with regard to each particular series of preferred stock that will describe the terms
and provisions of that series of preferred stock. The rights of the holders of any preferred stock that may be issued may adversely
affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties
to acquire a majority of our outstanding voting stock.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>Anti-Takeover Provisions</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Our certificate of incorporation provides for staggered terms
for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and
prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
more difficult a merger, tender offer or proxy contest involving us.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>Depositary Shares</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may, at our option, elect to offer fractional shares of preferred
stock, rather than full shares of preferred stock. If we exercise this option, we will issue to the public receipts for depositary
shares, and each of these depositary shares will represent a fraction, to be set forth in the applicable prospectus supplement,
of a share of a particular series of preferred stock.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The shares of any series of preferred stock underlying the depositary
shares will be deposited under a deposit agreement between us and a bank or trust company selected by us. The depositary will have
its principal office in the United States and a combined capital and surplus of at least $50,000,000. Subject to the terms of the
deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of preferred
stock underlying the depositary share, to all the rights and preferences of the preferred stock underlying that depositary share.
Those rights may include dividend, voting, redemption, conversion and liquidation rights.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The depositary shares will be evidenced by depositary receipts
issued under a deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares of
preferred stock underlying the depositary shares, in accordance with the terms of the offering. The following description of the
material terms of the deposit agreement, the depositary shares and the depositary receipts is only a summary and you should refer
to the forms of the deposit agreement and depositary receipts that will be filed with the SEC in connection with the offering of
the specific depositary shares.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Pending the preparation of definitive engraved depositary receipts,
the depositary, upon our written order, may issue temporary depositary receipts substantially identical to the definitive depositary
receipts but not in definitive form. These temporary depositary receipts would entitle their holders to all the rights of definitive
depositary receipts. Temporary depositary receipts would be exchangeable for definitive depositary receipts at our expense.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Dividends and Other Distributions</I></FONT>.
The depositary will distribute all cash dividends or other cash distributions received with respect to the underlying stock to
the record holders of depositary shares in proportion to the number of depositary shares owned by those holders.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">If there were a distribution other than in cash, the depositary
would distribute property received by it to the record holders of depositary shares that are entitled to receive the distribution,
unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary, with our approval,
would sell the property and distribute the net proceeds from the sale to the applicable holders.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Withdrawal of Underlying Preferred
Stock</I></FONT>. Unless we provide otherwise in a prospectus supplement, holders may surrender depositary receipts at the principal
office of the depositary and, upon payment of any unpaid amount due to the depositary, would be entitled to receive the number
of whole shares of underlying preferred stock and all money and other property represented by the related depositary shares. We
will not issue any partial shares of preferred stock. If the holder delivers depositary receipts evidencing a number of depositary
shares that represent more than a whole number of shares of preferred stock, the depositary will issue a new depositary receipt
evidencing the excess number of depositary shares to that holder.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Redemption of Depositary Shares</I></FONT>.
If a series of preferred stock represented by depositary shares were subject to redemption, the depositary shares would be redeemed
from the proceeds received by the depositary resulting from the redemption, in whole or in part, of that series of underlying stock
held by the depositary. The redemption price per depositary share would be equal to the applicable fraction of the redemption price
per share payable with respect to that series of underlying stock. Whenever we redeem shares of underlying stock that are held
by the depositary, the depositary will redeem, as of the same redemption date, the number of depositary shares representing the
shares of underlying stock so redeemed. If fewer than all the depositary shares are to be redeemed, the depositary shares to be
redeemed will be selected by lot or proportionately, as may be determined by the depositary.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Voting</I></FONT>. Upon receipt
of notice of any meeting at which the holders of the underlying stock are entitled to vote, the depositary will mail the information
contained in the notice to the record holders of the depositary shares underlying the preferred stock. Each record holder of the
depositary shares on the record date, which will be the same date as the record date for the underlying stock, will be entitled
to instruct the depositary as to the exercise of the voting rights pertaining to the amount of the underlying stock represented
by that holder's depositary shares. The depositary will then try, as far as practicable, to vote the number of shares of preferred
stock underlying those depositary shares in accordance with those instructions, and we will agree to take all actions which may
be deemed necessary by the depositary to enable the depositary to do so. The depositary will not vote the underlying shares to
the extent it does not receive specific instructions from the holders of depositary shares underlying the preferred stock.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Conversion of Preferred Stock</I></FONT>.
If the prospectus supplement relating to the depositary shares provides that the deposited preferred stock is convertible into
or exchangeable for common stock or preferred stock of another series of BioCryst or securities of any third party, the following
will apply. The depositary shares, as such, will not be convertible into or exchangeable for any securities of BioCryst or any
third party. Rather, any holder of the depositary shares may surrender the related depositary receipts to the depositary with written
instructions to instruct us to cause conversion or exchange of the preferred stock represented by the depositary shares into or
for whole shares of common stock or shares of another series of preferred stock of BioCryst or securities of the relevant third
party, as applicable. Upon receipt of those instructions and any amounts payable by the holder in connection with the conversion
or exchange, we will cause the conversion or exchange using the same procedures as those provided for conversion or exchange of
the deposited preferred stock. If only some of the depositary shares are to be converted or exchanged, a new depositary receipt
or receipts will be issued for any depositary shares not to be converted or exchanged.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Amendment and Termination of
the Depositary Agreement</I></FONT>. The form of depositary receipt evidencing the depositary shares and any provision of the deposit
agreement may be amended at any time by agreement between us and the depositary. However, any amendment which materially and adversely
alters the rights of the holders of depositary shares will not be effective unless the amendment has been approved by the holders
of at least a majority of the depositary shares then outstanding. The deposit agreement may be terminated by us or by the depositary
only if (a) all outstanding depositary shares have been redeemed or converted or exchanged for any other securities into which
the underlying preferred stock is convertible or exchangeable or (b) there has been a final distribution of the underlying stock
in connection with our liquidation, dissolution or winding up and the underlying stock has been distributed to the holders of depositary
receipts.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Charges of Depositary</I></FONT>.
We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements.
We will also pay charges of the depositary in connection with the initial deposit of the underlying stock and any redemption of
the underlying stock. Holders of depositary receipts will pay other transfer and other taxes and governmental charges and those
other charges, including a fee for any permitted withdrawal of shares of underlying stock upon surrender of depositary receipts,
as are expressly provided in the deposit agreement to be for their accounts.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Reports</I></FONT>. The depositary
will forward to holders of depositary receipts all reports and communications from us that we deliver to the depositary and that
we are required to furnish to the holders of the underlying stock.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Limitation on Liability</I></FONT>.
Neither we nor the depositary will be liable if either of us is prevented or delayed by law or any circumstance beyond our control
in performing our respective obligations under the deposit agreement. Our obligations and those of the depositary will be limited
to performance in good faith of our respective duties under the deposit agreement. Neither we nor the depositary will be obligated
to prosecute or defend any legal proceeding in respect of any depositary shares or underlying stock unless satisfactory indemnity
is furnished. We and the depositary may rely upon written advice of counsel or accountants, or upon information provided by persons
presenting underlying stock for deposit, holders of depositary receipts or other persons believed to be competent and on documents
believed to be genuine.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Resignation and Removal of Depositary</I></FONT>.
The depositary may resign at any time by delivering notice to us of its election to resign. We may remove the depositary at any
time. Any resignation or removal will take effect upon the appointment of a successor depositary and its acceptance of the appointment.
The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and must be a
bank or trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>DESCRIPTION OF STOCK PURCHASE CONTRACTS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The following is a general description of the terms of the stock
purchase contracts we may issue from time to time. Particular terms of any stock purchase contracts we offer will be described
in the prospectus supplement relating to such stock purchase contracts. Material U.S. federal income tax considerations applicable
to the stock purchase contracts will also be discussed in the applicable prospectus supplement. You should refer to the form of
stock purchase contract and stock purchase certificate that we will file with the SEC in connection with the offering of the specific
stock purchase contracts for more complete information.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may issue stock purchase contracts, including contracts obligating
holders to purchase from us, and obligating us to sell to holders, a specified number of shares of common stock, preferred stock
or depositary shares at a future date. The consideration per share of common stock, preferred stock or depositary shares may be
fixed at the time that the stock purchase contracts are issued or may be determined by reference to a specific formula set forth
in the stock purchase contracts. Any stock purchase contract may include anti-dilution provisions to adjust the number of shares
issuable pursuant to such stock purchase contract upon the occurrence of certain events.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The applicable prospectus supplement will describe the terms of
any stock purchase contracts in respect of which this prospectus is being delivered, including, to the extent applicable, the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the stock purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities
subject to purchase under the stock purchase contract, and the nature and amount of each of those securities, or the method of
determining those amounts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the stock purchase contracts are to be prepaid or not;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the stock purchase contracts will be issued as part of a unit and, if so, the other securities comprising the unit;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the stock purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance, or
level of the securities subject to purchase under the stock purchase contract;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any acceleration, cancellation, termination, or other provisions relating to the settlement of the stock purchase contracts;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the stock purchase contracts will be issued in full registered or global form.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may issue warrants to purchase our preferred stock, depositary
shares or common stock or any combination thereof. Warrants may be issued independently or together with any other securities in
the form of units, and may be attached to, or separate from, such securities. The terms of any warrants to be issued and a description
of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement. Each
series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company,
as warrant agent. You should refer to the form of warrant agreement and warrant that we file with the SEC in connection with the
offering of the specific warrants for more complete information.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The prospectus supplement will describe the terms of any warrants
being offered, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the title and the aggregate number of warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the price or prices at which the warrants will be issued;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the currency or currencies in which the price of the warrants will be payable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the securities or other rights, including rights to receive payment in cash or securities based on the value, rate or price
of one or more specified commodities, currencies, securities or indices, or any combination of the foregoing, purchasable upon
exercise of the warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the price at which, and the currency or currencies in which, the securities or other rights purchasable upon exercise of such
warrants may be purchased;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the periods during which, and places at which, the warrants are exercisable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the date or dates on which the warrants shall commence and the date or dates on which the warrants will expire;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the terms of any mandatory or optional call provisions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the price or prices, if any, at which the warrants may be redeemed at the option of the holder or will be redeemed upon expiration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the warrants will be sold separately or with other securities as part of a unit;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
with each such security;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>if applicable, the date on and after which the warrants and the related securities will be separately transferable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any provisions for the adjustment of the number or amount of securities receivable upon exercise of warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the identity of the warrant agent;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the exchanges, if any, on which the warrants may be listed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the maximum or minimum number of warrants which may be exercised at any time;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>if applicable, a discussion of any material United States federal income tax considerations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the warrants shall be issued in book-entry form; and</TD></TR></TABLE>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B></B></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may issue units consisting of one or more of the other securities
described in this prospectus in any combination, as described in a prospectus supplement. We may issue units in one or more series,
which will be described in a prospectus supplement. We will issue the units or hybrid securities under one or more unit agreements,
each referred to as a unit agreement, to be entered into between us and a bank or trust company, as unit agent. You should refer
to the form of unit agreement and unit certificate that we file with the SEC in connection with the offering of the specific units
for more complete information.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The applicable prospectus supplement will describe:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the designation and the terms of the units and of the securities constituting the units, including whether and under what circumstances
the securities comprising the units may be traded separately;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any additional terms of the governing unit agreement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any additional provisions for the issuance, payment, settlement, transfer or exchange of the units or of the preferred stock,
common stock, stock purchase contracts, depositary shares or warrants constituting the units; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any applicable United States federal income tax consequences.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -19.2pt; margin: 6pt 0 0 19.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B></B></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may sell the securities being offered hereby at prices and
under terms then prevailing, at prices related to the then current market price or in negotiated transactions from time to time
in one or more of the following ways:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>directly to one or more purchasers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through one or more underwriters on a firm commitment or best-efforts basis;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through broker-dealers, who may act as agents or principals, including a block trade in which a broker or dealer so engaged
will attempt to sell as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through agents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through remarketing firms;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>in privately negotiated transactions; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>in any combination of these methods of sale.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We will set forth in a prospectus supplement the terms of the
offering of securities, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the name or names of any underwriters, dealers or agents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the number of securities and purchase price of the securities being offered and the proceeds we will receive from the sale;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any underwriting discounts and commissions or agency fees and other items constituting underwriters&rsquo; or agents&rsquo;
compensation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any over-allotment options under which underwriters may purchase additional securities from us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any delayed delivery arrangements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any discounts or concessions allowed or re-allowed or paid to dealers; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any securities exchange on which the securities may be listed.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The distribution of the securities may be effected from time to
time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale,
at prices related to the prevailing market prices or at negotiated prices.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may designate agents who agree to use their reasonable efforts
to solicit purchases for the period of their appointment or to sell securities on a continuing basis. Agents may receive compensation
in the form of commissions, discounts or concessions from us. Agents may also receive compensation from the purchasers of the securities
for whom they sell as principals. Each particular agent will receive compensation in amounts negotiated in connection with the
sale, which might be in excess of customary commissions. Agents and any other participating broker-dealers may be deemed to be
&ldquo;underwriters&rdquo; within the meaning of Section 2(11) of the Securities Act of 1933 (the &ldquo;Securities Act&rdquo;)
in connection with sales of the securities. Accordingly, any commission, discount or concession received by them and any profit
on the resale of the securities purchased by them may be deemed to be underwriting discounts or commissions under the Securities
Act. We have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding
the sale of their securities. As of the date of this prospectus, there are no special selling arrangements between any broker-dealer
or other person and us. No period of time has been fixed within which the securities will be offered or sold.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">If required under applicable state securities laws, we will sell
the securities only through registered or licensed brokers or dealers. In addition, in some states, we may not sell securities
unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and complied with.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">If we use underwriters for a sale of securities, the underwriters
will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions, including
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations
of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.
We may change from time to time any initial public offering price and any discounts or concessions the underwriters allow or re-allow
or pay to dealers. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement
naming the underwriter the nature of any such relationship.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may use a remarketing firm to offer to sell the securities
in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own account
or as agents for us. These remarketing firms will offer or sell the securities pursuant to the terms of the securities. A prospectus
supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing
firm&rsquo;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">If we offer and sell securities through a dealer, we or an underwriter
will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices
to be determined by the dealer at the time of resale. Any such dealer may be deemed to be an underwriter of the securities so offered
and sold. The name of the dealer and the terms of the transactions will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may also sell securities directly to one or more purchasers
without using underwriters or agents. Underwriters, dealers and agents that participate in the distribution of the securities may
be underwriters as defined in the Securities Act and any discounts or commissions they receive from us and any profit on their
resale of the securities may be treated as underwriting discounts and commissions under the Securities Act.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We will identify in the applicable prospectus supplement any underwriters,
dealers or agents and will describe their compensation. We may have agreements with the underwriters, dealers and agents to indemnify
them against specified civil liabilities, including liabilities under the Securities Act. Underwriters, dealers and agents may
engage in transactions with or perform services for us in the ordinary course of their businesses.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may authorize agents, dealers or underwriters to solicit offers
to purchase securities at the public offering price under delayed delivery contracts. The terms of these delayed delivery contracts,
including when payment for and delivery of the securities sold will be made under the contracts and any conditions to each party&rsquo;s
performance set forth in the contracts, will be described in the applicable prospectus supplement. The compensation received by
underwriters, agents or dealers soliciting purchases of securities under delayed delivery contracts will be described in the applicable
prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We may enter into derivative or other hedging transactions with
third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the
applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered
by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use
securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock,
and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. We
may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may
sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus
and the applicable prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Unless otherwise specified in the related prospectus supplement,
all securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters
may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. We may apply to list any series of securities on an exchange, but we are not obligated to do so. Therefore, no assurance
can be given as to the liquidity of, or the trading market for, any series of securities.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Any underwriter may engage in overallotment, stabilizing transactions,
short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales
in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the
securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters
to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction
to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced,
the underwriters may discontinue any of the activities at any time. These transactions may be effected on The NASDAQ Global Select
Market or otherwise.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Any underwriters who are qualified market makers on The NASDAQ
Global Select Market may engage in passive market making transactions in the common stock on The NASDAQ Global Select Market in
accordance with Rule 103 of Regulation M, during the business day before the pricing of the offering, before the commencement of
offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be
identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are lowered below the passive market maker&rsquo;s bid, however, the
passive market maker&rsquo;s bid must then be lowered when certain purchase limits are exceeded.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We will bear all costs, expenses and fees in connection with the
registration of the securities, as well as the expense of all commissions and discounts, if any, attributable to sales of the securities
by us.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>LEGAL MATTERS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Gibson, Dunn &amp; Crutcher LLP has rendered an opinion with respect
to the validity of the securities being offered by this prospectus. We have filed this opinion as an exhibit to the registration
statement of which this prospectus is a part. If counsel for any underwriters passes on legal matters in connection with an offering
made by this prospectus, we will name that counsel in the prospectus supplement relating to that offering.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>EXPERTS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Ernst &amp; Young LLP, independent registered public accounting
firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December
31, 2015, and the effectiveness of our internal control over financial reporting as of December 31, 2015, as set forth in their
reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements
are incorporated by reference in reliance on Ernst &amp; Young LLP's reports, given on their authority as experts in accounting
and auditing.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B></B></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We file electronically with the SEC our annual reports on Form
10-K, quarterly interim reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. We make available
on or through our website, http://www.biocryst.com, free of charge, copies of these filings as soon as reasonably practicable after
we electronically file them with or furnish them to the SEC. The information on our website is not incorporated by reference into
this prospectus. You can also request copies of such documents by contacting our Investor Relations Department at 4505 Emperor
Blvd., Suite 200, Durham, North Carolina 27703 or sending an email to investorrelations@biocryst.com. You may read and copy any
document we file at the SEC&rsquo;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can also obtain copies
of this information by mail from the Public Reference Room of the SEC at prescribed rates. You may obtain information on the operation
of the Public Reference Room by calling the SEC at (800) SEC-0330.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The SEC also maintains an Internet site that contains reports,
proxy and information statements, and other information about issuers, like BioCryst, that file electronically with the SEC. The
address of that site is http://www.sec.gov. Unless specifically listed below under &ldquo;Incorporation of Certain Documents by
Reference&rdquo; the information contained on the SEC website is not incorporated by reference into this prospectus.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We have filed with the SEC a registration statement on Form S-3
that registers the securities we are offering. The registration statement, including the attached exhibits and schedules, contains
additional relevant information about us and our securities. The rules and regulations of the SEC allow us to omit certain information
included in the registration statement from this prospectus.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 12pt 0.5in 0"><B>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The SEC allows us to &ldquo;incorporate by reference&rdquo; information
into this prospectus. This means that we can disclose important information to you by referring you to another document filed separately
with the SEC. The information incorporated by reference is considered to be part of this prospectus, except for any information
that is superseded by information that is included directly in this document.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">This prospectus includes by reference the documents listed below
that we have previously filed with the SEC and that are not included in or delivered with this document. They contain important
information about us and our financial condition.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 26, 2016;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our Current Reports on Form 8-K filed with the SEC on January 8, 2016 and February 8, 2016; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The description of our common stock which is contained in our Registration Statement on Form 8-A (File No. 000-23186) filed
with the SEC on January 7, 1994, together with the amendment thereto filed with the SEC on March 14, 1994, including any other
amendment or reports filed for the purpose of updating such description.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">All documents filed by us pursuant to Section 13(a), 13(c), 14
or 15(d) of the Exchange Act on or after the date of this Amendment No. 1 and prior to its effectiveness and on or after the date
of this prospectus and prior to the termination of our offering of securities shall be deemed to be incorporated by reference herein
and to be a part of this prospectus from the date of filing of such documents, excluding any information furnished under Item 2.02
or Item 7.01 of any Current Report on Form 8-K and exhibits filed on such form that are related to such items. Any statement contained
in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to
the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated
by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">You can obtain any of the documents incorporated by reference
in this prospectus from us without charge, excluding any exhibits to those documents unless the exhibit is specifically incorporated
by reference as an exhibit to this prospectus. You can obtain documents incorporated by reference in this prospectus at no cost
by requesting them in writing or by telephone from us at the following address:</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">Investor Relations<BR>
BioCryst Pharmaceuticals, Inc.<BR>
4505 Emperor Blvd., Suite 200<BR>
Durham, North Carolina 27703<BR>
(919) 859-1302</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">We have not authorized anyone else to make additional representations
or to provide you with information other than information provided or incorporated by reference in this prospectus or any prospectus
supplement. We take no responsibility for, and can provide no assurances as to the reliability of, any other information that others
may give you or representations that others may make. If you are in a jurisdiction where offers to sell, or solicitations of offers
to purchase, the securities offered by this document are unlawful, or if you are a person to whom it is unlawful to direct these
types of activities, then the offer presented in this document does not extend to you.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 12pt 0 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><IMG SRC="logo.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 12pt 0 0"><B>BioCryst Pharmaceuticals, Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>$150,000,000</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Common Stock<BR>
Preferred Stock<BR>
Depositary Shares<BR>
Stock Purchase Contracts<BR>
Warrants<BR>
Units</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>PROSPECTUS </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0pt 0pt">,
2016</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B></B></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>PART II</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>ITEM 14.&#9;OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The following table sets forth all expenses payable by the registrant
in connection with the issuance and distribution of the securities, other than underwriting discounts and commissions. The registrant
will bear all of such expenses. All the amounts shown are estimates, except the registration fee.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; font-size: 10pt; text-align: left; text-indent: 0in">Registration fee&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">15,105</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Accounting fees and expenses&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Legal fees and expenses&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">150,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Printing and engraving&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0in">Miscellaneous&#9;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">34,895</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.25pt; text-indent: 0in; padding-left: 10pt">Total&#9;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">300,000</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Section 145 of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;)
sets forth the circumstances in which a Delaware corporation is permitted and/or required to indemnify its directors and officers.
The DGCL permits a corporation to indemnify its directors and officers in certain proceedings if the director or officer has complied
with the standard of conduct set out in the DGCL. The standard of conduct requires that the director or officer must have acted
in good faith, in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and,
with respect to matters in a criminal proceeding, the director or officer must have had no reason to believe that his or her conduct
was unlawful. With respect to suits by or in the right of the corporation, the DGCL permits indemnification of directors and officers
if the person meets the standard of conduct, except that it precludes indemnification of directors and officers who are adjudged
liable to the corporation, unless the Court of Chancery or the court in which the corporation&rsquo;s action or suit was brought
determines that the director or officer is fairly and reasonably entitled to indemnity for expenses. To the extent that a present
or former director or officer of the corporation is successful on the merits or otherwise in his or her defense of a proceeding,
the corporation is required to indemnify the director or officer against reasonable expenses incurred in defending himself or herself.
The rights provided in Section 145 of the DGCL are not exclusive, and the corporation may also provide for indemnification under
bylaw, agreement, vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The registrant&rsquo;s Third Restated Certificate of Incorporation,
as amended (the &ldquo;Certificate of Incorporation&rdquo;), provides for indemnification of any director or officer who was or
is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative, by reason of the fact that he is or was, or has agreed to become, a director or officer
of the registrant, or is or was serving, or agreed to serve, at the request of the registrant, as a director, officer or trustee
of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee
benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf
in connection with such action, suit or proceeding and any appeal therefrom, in each case to the fullest extent permitted by the
DGCL. The registrant shall not indemnify any person seeking indemnification in connection with a proceeding or part thereof initiated
by such person unless the initiation was approved by the Board of Directors of the registrant. The Certificate of Incorporation
further provides for permissible indemnification of employees and other agents to the maximum extent permitted by the DGCL and
the Certificate of Incorporation with respect to directors and officers.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Section 102(b)(7) of the DGCL provides that a corporation may
relieve its directors from personal liability to the corporation or its stockholders for monetary damages for any breach of their
fiduciary duty as directors except for (i) a breach of the duty of loyalty; (ii) acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law; (iii) willful or negligent violations of certain provisions in the DGCL imposing
certain requirements with respect to stock repurchases, redemptions and dividends; or (iv) for any transactions from which the
director derived an improper personal benefit. The registrant&rsquo;s Certificate of Incorporation provides that no directors of
the registrant shall be liable to the registrant or its stockholders for monetary damages for breach of fiduciary duty as a director
to the fullest extent permitted by the DGCL.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">In addition, the registrant currently maintains liability insurance
for its directors and officers insuring them against certain liabilities asserted against them in their capacities as directors
or officers or arising out of such status.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The indemnification provisions noted above may be sufficiently
broad to permit indemnification of the registrant&rsquo;s officers and directors for liabilities arising under the Securities Act.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>ITEM 16. &#9;EXHIBITS.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">See the Exhibit Index attached to this registration statement
and incorporated herein by reference.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><B>ITEM 17. &#9;UNDERTAKINGS.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The undersigned registrant hereby undertakes:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(a) To include any prospectus required by Section 10(a)(3) of
the Securities Act;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(b) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo;
table in the effective registration statement; and</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(c) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or any material change to such information in the registration
statement.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><I>Provided, however,</I></FONT>
that paragraphs (1)(a), (1)(b) and (1)(c) do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13
or 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus
filed pursuant to Rule 424(b) that is part of the registration statement.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(4) That, for the purpose of determining liability under the Securities
Act to any purchaser:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(a) Each prospectus filed by the registrant pursuant to Rule 424(b)(3)
shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in
the registration statement; and</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(b) Each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i),
(vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be
part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in the registration statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.
<I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part
of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made
in any such document immediately prior to such effective date.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(5) That, for the purpose of determining liability of the registrant
under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes
that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the
underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means
of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to
offer or sell such securities to such purchaser:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(a) Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(b) Any free writing prospectus relating to the offering prepared
by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(c) The portion of any other free writing prospectus relating
to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of
the undersigned registrant; and</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">(d) Any other communication that is an offer in the offering made
by the undersigned registrant to the purchaser.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to Section
13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions described
in Item 15, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B></B></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 12pt 0 0">Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Durham, State of North Carolina, on February 26, 2016.</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 4in">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 4in">By: <U>/s/ Jon P. Stonehouse&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 4.25in">Jon P. Stonehouse</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 4.25in">President and Chief Executive Officer</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 12pt 0 0">Each of the undersigned officers and directors of BioCryst Pharmaceuticals,
Inc. hereby severally constitutes and appoints Jon P. Stonehouse, Thomas R. Staab and Alane Barnes, and each of them singly, his
or her true and lawful attorneys-in-fact and agent, with full power to them and each of them singly, with full and several power
of substitution and resubstitution, to sign for him or her in his or her name in the capacities indicated below, any and all amendments
(including post-effective amendments or any abbreviated Registration Statement, and any amendments thereto, filed pursuant to Rule
462(b) under the Securities Act of 1933, as amended), and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission; granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to perform any other act on behalf of the undersigned required to be done in the premises, hereby ratifying
and confirming all that said attorneys-in-fact and agents, or any of them or their substitutes or resubstitutes, lawfully do or
cause to be done by virtue hereof.</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 12pt 0 0">Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the capacities indicated on February 26, 2016.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 48%; text-align: center; text-indent: 0in"><font style="font-size: 10pt"><b>Name</b></font></td>
    <td style="width: 2%; text-align: center; text-indent: 0in">&nbsp;</td>
    <td style="width: 50%; text-align: center; text-indent: 0in"><font style="font-size: 10pt"><b>Title</b></font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Jon P. Stonehouse&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Jon P. Stonehouse</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">President, Chief Executive Officer and Director</font><br>
<font style="font-size: 10pt">(Principal Executive Officer)</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Thomas R. Staab II&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Thomas R. Staab II</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</font><br>
<font style="font-size: 10pt">(Principal Financial Officer and </font><br>
<font style="font-size: 10pt">Principal Accounting Officer)</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ George B. Abercrombie&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">George B. Abercrombie</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Fred E. Cohen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Fred E. Cohen, M.D., D.Phil</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Stanley C. Erck&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><font style="font-size: 10pt">Stanley</font> C. Erck</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Nancy Hutson, Ph.D.</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Robert A. Ingram&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Robert A. Ingram</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Kenneth B. Lee, Jr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Kenneth B. Lee, Jr.</P></td>
    <td rowspan="2" style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Sanj K. Patel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Sanj K. Patel</P></td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><u>/s/ Charles A. Sanders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Charles A. Sanders, M.D.</P></td>
    <td style="vertical-align: top; text-indent: 0in">&nbsp;</td>
    <td style="text-align: center; text-indent: 0in"><font style="font-size: 10pt">Director</font></td></tr>
</table>
<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B></B></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>EXHIBIT INDEX</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 13%; text-decoration: underline; text-indent: 0in"><font style="font-size: 10pt"><b><u>Exhibit No.</u></b></font></td>
    <td style="width: 2%; text-indent: 0in">&nbsp;</td>
    <td style="width: 85%; text-decoration: underline; text-indent: 0in"><font style="font-size: 10pt"><b><u>Description</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">1.1*</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Form of Underwriting Agreement.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.1</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Third Restated Certificate of Incorporation of the Company. Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K filed December 22, 2006 (File No. 000-23186).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.2</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of the Company. Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K filed July 24, 2007 (File No. 000-23186).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.3</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of the Company.&nbsp;&nbsp;Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K filed May 7, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.4</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock.&nbsp;&nbsp;Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K filed November 4, 2008 (File No. 000-23186).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.5</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock of the Company.&nbsp;&nbsp;Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K filed May 7, 2014 (File No. 000-23186).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.6</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Amended and Restated Bylaws of the Company effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&rsquo;s Form 8-K filed November 4, 2008 (File No. 000-23186).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.7</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Specimen Certificate for Registrant&rsquo;s Common Stock. Incorporated by reference to Exhibit 4.7 to the Company&rsquo;s Form S-3 filed November 28, 2008 (File No. 333-155783).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.8*</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Certificate of Designation of Preferred Stock.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.9*</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Form of Warrant Agreement (including form of Warrant).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.10*</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Form of Deposit Agreement with respect to Depositary Shares (including form of Depositary Receipt).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.11*</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Form of Stock Purchase Contract (including form of Stock Purchase Certificate).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">4.12*</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Form of Unit Agreement (including form of Unit Certificate).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">5.1</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Opinion of Gibson, Dunn &amp; Crutcher LLP.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">23.1</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">23.2</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Consent of Gibson, Dunn &amp; Crutcher LLP (included in Exhibit 5.1).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in"><font style="font-size: 10pt">24.1</font></td>
    <td style="text-indent: 0in">&nbsp;</td>
    <td style="text-indent: 0in"><font style="font-size: 10pt">Power of Attorney (included on the signature page of this Registration Statement).</font></td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0">______________________</P>

<P STYLE="font-size: 10pt; margin: 0">* To be filed by amendment hereto or pursuant to a Current Report on Form 8-K to be
incorporated herein by reference.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exh_51.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 5.1</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><IMG SRC="dunn_logo.jpg" ALT=""></TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%"><IMG SRC="dunn_header.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">Client: 12412-00001</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-indent: 0.5in"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 30pt 0 24pt">BioCryst Pharmaceuticals, Inc.<BR>
4505 Emperor Blvd., Suite 200<BR>
Durham, North Carolina 27703</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Re:</TD><TD>BioCryst Pharmaceuticals, Inc.<BR>
Registration Statement on Form S-3</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Ladies and Gentlemen:</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">We have acted as counsel to BioCryst Pharmaceuticals, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation and filing with the Securities and Exchange Commission (the
&ldquo;<U>Commission</U>&rdquo;) of a Post-Effective Amendment, dated as of the date hereof, to the Registration Statement on Form
S-3, File No. 333-202466 (as amended, the &ldquo;<U>Registration Statement</U>&rdquo;), filed under the Securities Act of 1933,
as amended (the &ldquo;<U>Securities Act</U>&rdquo;) on March 3, 2015, relating to the registration under the Securities Act and
the proposed issuance and sale from time to time pursuant to Rule 415 under the Securities Act, together or separately and in one
or more series (if applicable) of:</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in"><FONT STYLE="font-size: 10pt"></FONT>(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>shares of the
Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;<U>Common Stock</U>&rdquo;);</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in"><FONT STYLE="font-size: 10pt"></FONT>(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>shares of the
Company&rsquo;s preferred stock, par value $0.01 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;);</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in"><FONT STYLE="font-size: 10pt"></FONT>(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>depositary
shares each representing a fraction of a share of a particular series of Preferred Stock (the &ldquo;<U>Depositary Shares</U>&rdquo;);</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in"><FONT STYLE="font-size: 10pt">
</FONT>(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>contracts for
the purchase or sale of Common Stock, Preferred Stock or Depositary Shares (the &ldquo;<U>Purchase Contracts</U>&rdquo;);</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in"><FONT STYLE="font-size: 10pt">
</FONT>(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>warrants for
the purchase of Common Stock, Preferred Stock, Depositary Shares or any combination thereof (the &ldquo;<U>Warrants</U>&rdquo;);
and</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>units of the Company comprised of any combination of Common Stock, Preferred Stock, Depositary Shares, Purchase Contracts
or Warrants (the &ldquo;<U>Units</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"></P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center; font-size: 10pt"><img src="exh51footer.jpg" alt="" style="height: 26px; width: 424px"></td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 12pt 0 0"><IMG SRC="dunn_logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Page 2</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">The Common Stock, Preferred Stock, Depositary Shares, Purchase Contracts, Warrants
and Units are collectively referred to herein as the &ldquo;<U>Securities</U>.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">In arriving at the opinions expressed below, we have examined originals, or copies
certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen Common
Stock certificate and such other documents, corporate records, certificates of officers of the Company and of public officials
and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination, we have
assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents
submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts
material to these opinions, we have relied to the extent we deemed appropriate and without independent investigation upon statements
and representations of officers and other representatives of the Company and others.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">We have assumed without independent investigation that:</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the time any Securities are sold pursuant to the Registration Statement (the &ldquo;<U>Relevant Time</U>&rdquo;), the
Registration Statement and any supplements and amendments thereto (including post-effective amendments) will be effective and
will comply with all applicable laws;</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the Relevant Time, a prospectus supplement will have been prepared and filed with the Commission describing the Securities
offered thereby and all related documentation and will comply with all applicable laws;</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Securities will be issued and sold in the manner stated in the Registration Statement and the applicable prospectus
supplement;</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the Relevant Time, all corporate or other action required to be taken by the Company to duly authorize each proposed
issuance of Securities and any related documentation (including (a) the due reservation of any shares of Common Stock or Preferred
Stock for issuance upon exercise, conversion or exchange of any Securities for Common Stock or Preferred Stock (a &ldquo;<U>Convertible
Security</U>&rdquo;), and (b) the execution (in the case of certificated Securities), delivery and performance of the Securities
and any related documentation referred to in paragraphs 1 through 6 below) shall have been duly completed and shall remain in
full force and effect;</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>upon issuance of any Common Stock or Preferred Stock, including upon exercise, conversion or exchange of any Convertible
Security, the total number of shares of Common Stock or Preferred Stock issued and outstanding will not exceed the total number
of shares of Common Stock or Preferred Stock, as applicable, that the Company is then authorized to issue under its certificate
of incorporation and other relevant documents;</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 12pt 0pt 0pt; font-size: 10pt"><IMG SRC="dunn_logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Page 3</P>


<P STYLE="margin: 12pt 0 0; font-size: 10pt; text-indent: 1.25in">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the Relevant Time, a definitive purchase, underwriting or similar agreement and any other necessary agreement with respect
to any Securities offered or issued will have been duly authorized by all necessary corporate or other action of the Company and
duly executed and delivered by the Company and the other parties thereto.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Based on the foregoing and in reliance thereon, and subject to the assumptions, exceptions,
qualifications and limitations set forth herein, we are of the opinion that:</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to any shares of Preferred Stock, when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>the certificate of designations relating to such Preferred Stock (the &ldquo;<U>Certificate of Designations</U>&rdquo;) has
been duly executed and filed with the Office of the Secretary of State of the State of Delaware,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>such shares have been duly executed (in the case of certificated shares) and delivered either (i) in accordance with the applicable
definitive purchase, underwriting or similar agreement and for the consideration therefor provided for therein or (ii) upon exercise,
conversion or exchange of any Convertible Security and for any additional consideration specified in such Convertible Security
or the instrument governing such Convertible Security providing for such conversion or exercise, which consideration (including
any consideration paid for such Convertible Security), on a per-share basis, shall in either event not be less than the par value
of the Preferred Stock, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>any such Convertible Security was previously validly issued and is fully paid and non-assessable (in the case of an equity
Security) or is a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0 0.75in">such shares of Preferred Stock will be validly issued,
fully paid and non-assessable.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to Depositary Shares, when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>a deposit agreement relating to such Depositary Shares (&ldquo;<U>Deposit Agreement</U>&rdquo;) has been duly executed and
delivered by the Company and the depositary appointed by the Company,</TD></TR></TABLE>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="dunn_logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Page 4</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>the terms of the Depositary Shares have been established in accordance with the Deposit Agreement, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>the depositary receipts representing the Depositary Shares have been duly executed and countersigned (in the case of certificated
Depositary Shares), registered and delivered in accordance with the related Deposit Agreement and the applicable definitive purchase,
underwriting or similar agreement for the consideration provided therein,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0 0.75in">the depositary receipts evidencing the Depositary Shares
will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT>3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>With respect to
shares of Common Stock, when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>such shares of Common Stock have been duly executed (in the case of certificated shares) and delivered either (i) in accordance
with the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, or (ii)
upon conversion or exercise of any Convertible Security, in accordance with the terms of such Convertible Security or the instrument
governing such Convertible Security providing for such conversion or exercise, and for any additional consideration specified therein,
which consideration (including any consideration paid for such Convertible Security), on a per-share basis, shall in either event
not be less than the par value of the Common Stock, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>any such Convertible Security was previously validly issued and is fully paid and non-assessable (in the case of an equity
Security) or is a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0 0.75in">such shares of Common Stock will be validly issued, fully
paid and non-assessable.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT>4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>With respect to
any Purchase Contracts, when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>the related purchase contract agreement (&ldquo;<U>Purchase Contract Agreement</U>&rdquo;), if any, has been duly executed
by the Company and each other party thereto,</TD></TR></TABLE>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="dunn_logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Page 5</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>the terms of the Purchase Contracts have been established in accordance with the Purchase Contract Agreement, if any, or the
applicable definitive purchase, underwriting or similar agreement,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>the terms of any collateral or security arrangements relating to such Purchase Contracts have been established and the agreements
thereto have been validly executed and delivered by each of the parties thereto and any collateral has been deposited with the
collateral agent, if applicable, in accordance with such arrangements, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>such Purchase Contracts have been executed (in the case of certificated Purchase Contracts) and delivered in accordance with
the Purchase Contract Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration
provided for therein,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0 0.75in">such Purchase Contracts will be legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT>5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>With respect to
any Warrants, when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>the warrant agreement relating to such Warrants (the &ldquo;<U>Warrant Agreement</U>&rdquo;), if any, has been duly executed
and delivered by the Company and each other party thereto,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>the terms of the Warrants have been established in accordance with the Warrant Agreement, if any, and the applicable definitive
purchase, underwriting or similar agreement, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>the Warrants have been duly executed (in the case of certificated Warrants) and delivered in accordance with the Warrant Agreement,
if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0 0.75in">such Warrants will be legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to any Units, when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>the unit agreement relating to the Units (the &ldquo;<U>Unit Agreement</U>&rdquo;), if any, has been duly executed and delivered
by the Company and each other party thereto,</TD></TR></TABLE>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="dunn_logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Page 6</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>the terms of the Units have been duly established in accordance with the Unit Agreement, if any, and the applicable definitive
purchase, underwriting or similar agreement, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>the Units have been duly executed (in the case of certificated Units) and delivered in accordance with the Unit Agreement,
if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 12pt 0 0 0.75in">the Units will be legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">The opinions expressed above are subject to the following exceptions, qualifications,
limitations and assumptions:</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT>A.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>We render no opinion
herein as to matters involving the laws of any jurisdiction other than the State of New York, the United States of America and,
for purposes of paragraphs 1 and 3 above, the Delaware General Corporation Law. This opinion is limited to the effect of the current
state of the laws of the State of New York, the Delaware General Corporation Law, the United States of America and the facts as
they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such laws
or the interpretations thereof or such facts.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0">B.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The opinions above with respect to the depositary receipts representing the Depositary Shares, the Deposit Agreement, the
Purchase Contracts, any Purchase Contract Agreement, the Warrants, the Warrant Agreement, the Units and the Unit Agreement (collectively,
the &ldquo;<U>Documents</U>&rdquo;) are each subject to (i) the effect of any bankruptcy, insolvency, reorganization, moratorium,
arrangement or similar laws affecting the rights and remedies of creditors generally, including without limitation the effect
of statutory or other laws regarding fraudulent transfers or preferential transfers, (ii) general principles of equity, including
without limitation concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific
performance, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding
in equity or at law and (iii) the provisions of the sixth article of the Company&rsquo;s Third Restated Certificate of Incorporation.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT>C.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>We express no
opinion regarding the effectiveness of (i) any waiver of stay, extension or usury laws and (ii) provisions relating to indemnification,
exculpation or contribution, to the extent such provisions may be held unenforceable as contrary to public policy or federal or
state securities laws.</P>

<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 12pt 0pt 0pt"><IMG SRC="dunn_logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Page 7</P>


<P STYLE="font-size: 10pt; text-indent: 1.25in; margin: 12pt 0 0">D.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent relevant to our opinions in paragraphs 2, 4, 5 and 6 and not covered by our opinions in paragraphs 1 or 3,
we have assumed that any securities, currencies or commodities underlying, comprising or issuable upon exchange, conversion or
exercise of any Depositary Shares, Purchase Contracts, Warrants, or Units are validly issued, fully paid and non-assessable (in
the case of an equity security) or a legal, valid and binding obligation of the issuer thereof, enforceable against such issuer
in accordance with its terms.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">You have informed us that you intend to issue Securities from time to time on a delayed
or continuous basis, and we understand that prior to issuing any Securities pursuant to the Registration Statement (i) you will
advise us in writing of the terms thereof, and (ii) you will afford us an opportunity to (x) review the operative documents pursuant
to which such Securities are to be issued or sold (including the applicable offering documents), and (y) file such supplement or
amendment to this opinion (if any) as we may reasonably consider necessary or appropriate.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">We consent to the filing of this opinion as an exhibit to the Registration Statement,
and we further consent to the use of our name under the caption &ldquo;Legal Matters&rdquo; in the Registration Statement and the
prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Very truly yours,</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">/s/ Gibson, Dunn &amp; Crutcher LLP</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exh_231.htm
<DESCRIPTION>EXHIBIT 231
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 23.1</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Consent of Independent Registered Public Accounting Firm</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We consent to the reference to our firm under the caption &ldquo;Experts&rdquo;
in this Post-Effective Amendment No. 1 to the Registration Statement (Form S-3 No. 333-202466) and related Prospectus of BioCryst
Pharmaceuticals, Inc. for the registration of common stock, preferred stock, depositary shares, stock purchase contracts, warrants,
and units and to the incorporation by reference therein of our reports dated February 26, 2016, with respect to the consolidated
financial statements of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst
Pharmaceuticals, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2015, filed with the Securities
and Exchange Commission.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Raleigh, North Carolina</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>dunn_header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dunn_header.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !% (<# 2(  A$! Q$!_\0
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MVI]FW++C_5D>8"IR"<D<\ 5-I&HZJ?#VHQ:=;R7DR1DQ7@ED(:0Q9Z3<DAL
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>dunn_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dunn_logo.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X01_17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    4    <@$R  (    4    AH=I  0    !    G    ,@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P(#<N,  R,#$S.C$Q.C S(# S.C0X
M.C W      .@ 0 #     ?__  "@ @ $     0   ,.@ P $     0   !H
M        !@$#  ,    !  8   $:  4    !   !%@$;  4    !   !'@$H
M  ,    !  (   (!  0    !   !)@("  0    !   #40        !(
M 0   $@    !_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  @&!@<&!0@'!P<)
M"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y
M/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  - &(# 2(
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M./-.XV=M%O5C;J#,YW" SGSFCBE46R;%< R7$IB(R?<T9?WR.*+]"8EVF=9
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M6+3R#4^SH (@   #@ 5*]J5&6G__V0
M    _^$22&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*
M/#]A9&]B92UX87 M9FEL=&5R<R!E<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL
M;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N
M."XR+3,S+"!F<F%M97=O<FL@,2XU)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C)R!X
M;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C O)SX*"B \<F1F
M.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED.C Y9&9D-61C+30S964M,3%E,RTX
M9#@T+6,R8S)D9F4P-&,T,R<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R<^"B @/'AA<$U-.D1O8W5M96YT240^861O
M8F4Z9&]C:60Z<&AO=&]S:&]P.C Y9&9D-61A+30S964M,3%E,RTX9#@T+6,R
M8S)D9F4P-&,T,SPO>&%P34TZ1&]C=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&%P;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M)W<G/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P@ 1"  : ,,# 2(  A$! Q$!_\0 '0   @(" P$
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M0 'Q(!X#_4/ST9YVD:8S2F9]@\ID<R,'4HP9R=CLA*-DG925/C]/_\0 -1
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M /C*_P#ZXYT#5**+NW6,#U-VX -UV?(0$)AF1]PS$YCUXYJT8;5G4="T8F^
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MFQ*K)2=FI7NWJ]&P9>Z744V JGN_5$JP4>Z)X6A"P2E0"M2EC +6 Q@0 1Q
MC$1VB(QP5[PDUKIYZES3WV-.LMSZ]9M%J"=GYZLEWCAK*51:WOQXBT4FZW8Q
MZ=>VXF6&X^(-DQ'QPD]1J1:*O,$C>U\0HQF9%@"#1$6C,SAL1U(^"QP"PSM
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M8RRF<@U GY__Q  @$ $! 0$!  $$ P         !$0 A,1! 05&A89&Q_]H
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K5($,YH?\L%P*NRA%'R*@\F4J$A,.E$^HEG#2Y0!:5 5 GU<J'F.1&K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exh51footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh51footer.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : :@# 2(  A$! Q$!_\0
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MF>HJ_!H.F6T2QQ6V%7R\9=B?D<R+R3SAF)_&FQ^'=,B<&.!T41^6465PK#!
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M99<=3D=.HB&HG5+KSS:G33&@@"!O-W\[]^>,=,8]ZNT4 >;00:U%>1K)!?O
M)?L+ !C^[M294D _Z:89<]\@59M->U]C%+,\S0"X"A%@_>2JRQG )C"G!+@C
MY?9CMKT"B@#A]+;6;:"UMY5FGB,D+XE@SY6;A@P!QGA<')R1UJ&;6]?L[:V:
MYDNF:Y$9(CME$BL?-RJ J1QM0G()QD]Z[ZJU]:V]W;%+F"*9000LB!@#Z\T
M<5::CJ*32S/J\[PS_9FDN88!(B+Y+9>,;,8,@"GCC/0'FM&PU/6Q/!=:EYD4
M&\K/!]G^6-!;"0MG&[._(ZX[=:ZN.-(HUCC1411A548 'H!2D!@00"#P0>]
M'/>()+>YBTB:;SWL))]\GE+)DJ8GVY"?-UV_CBJ3RW+:-I4.I"],<<@-\ K[
M_+*OY>XKR>0F['?KQ77]** *&D31M8Q0H+L&.-3B[4^9M.<;B>IP/J._-%7Z
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] ,8# 2(  A$! Q$!_\0
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M0PR7""W9UX(5I6W8^HX_&O7_  MIMGIOA'2[&S1/LJ6D8  X;*@DGUSDG\:
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MJTUC9(3#-:RB:24?--A<@;>@7/;K[UO:W\,;W0M:CN])22\T]]XV 9DB)1@
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
